Patents by Inventor John D. Haley
John D. Haley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11978541Abstract: Medical information is communicated between different entities. Personalized models of peoples' understanding of a medical field are created. Role information is used to assign user-appropriate ontologies. More information than mere role may be used for assigning ontologies, such as information on past medical history. The concepts and relationships in different ontologies may be linked, providing a translation from one personalized model to another. The terminology with similar or the same concepts and/or relationships is output for a given user based on their model.Type: GrantFiled: August 9, 2019Date of Patent: May 7, 2024Assignee: CERNER INNOVATION, INC.Inventor: John D. Haley
-
Publication number: 20190362825Abstract: Medical information is communicated between different entities. Personalized models of peoples' understanding of a medical field are created. Role information is used to assign user-appropriate ontologies. More information than mere role may be used for assigning ontologies, such as information on past medical history. The concepts and relationships in different ontologies may be linked, providing a translation from one personalized model to another. The terminology with similar or the same concepts and/or relationships is output for a given user based on their model.Type: ApplicationFiled: August 9, 2019Publication date: November 28, 2019Inventor: John D. Haley
-
Patent number: 10490306Abstract: Medical information is communicated between different entities. Personalized models of peoples' understanding of a medical field are created. Role information is used to create the personalized model. More information than mere role may be used for at least one of the personalized models, such as information on past medical history. The personalized models link to various subsets of base medical ontologies for one or more medical subjects. The concepts and relationships in these ontologies formed by the linking may be matched, providing a translation from one personalized model to another. The terminology with similar or the same concepts and/or relationships is output for a given user based on their model.Type: GrantFiled: February 20, 2015Date of Patent: November 26, 2019Assignee: CERNER INNOVATION, INC.Inventor: John D. Haley
-
Patent number: 10424403Abstract: Adaptive medical data collection for medical entities may involve managing content by receiving data indicating a context, identifying at least one application or knowledge base associated with the context, designating the identified application or knowledge base as active, and accessing the active application or knowledge base to provide information at an interface point for a medical professionals and a patient.Type: GrantFiled: January 28, 2014Date of Patent: September 24, 2019Assignee: Siemens AktiengesellschaftInventors: Glenn Fung, Joseph Marcus Overhage, Jan DeHaan, Faisal Farooq, Balaji Krishnapuram, John D Haley, Sebastian Philipp Brandt, Luigi Iannone, Nicholas Drummond, Ignazio Palmisano
-
Publication number: 20160246946Abstract: Medical information is communicated between different entities. Personalized models of peoples' understanding of a medical field are created. Role information is used to create the personalized model. More information than mere role may be used for at least one of the personalized models, such as information on past medical history. The personalized models link to various subsets of base medical ontologies for one or more medical subjects. The concepts and relationships in these ontologies formed by the linking may be matched, providing a translation from one personalized model to another. The terminology with similar or the same concepts and/or relationships is output for a given user based on their model.Type: ApplicationFiled: February 20, 2015Publication date: August 25, 2016Inventor: John D. Haley
-
Publication number: 20160158235Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors.Type: ApplicationFiled: December 8, 2015Publication date: June 9, 2016Inventors: John D. HALEY, Graeme GRIFFIN, Lukas A. AMLER, David A. EBERHARD, Robert L. YAUCH
-
Patent number: 9244058Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors.Type: GrantFiled: December 12, 2011Date of Patent: January 26, 2016Assignee: OSI Pharmaceuticals, LLCInventors: John D. Haley, Graeme Griffin, Lukas A. Amler, David A. Eberhard, Robert L. Yauch
-
Publication number: 20140214451Abstract: Adaptive medical data collection for medical entities may involve managing content by receiving data indicating a context, identifying at least one application or knowledge base associated with the context, designating the identified application or knowledge base as active, and accessing the active application or knowledge base to provide information at an interface point for a medical professionals and a patient.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicant: Siemens Medical Solutions USA, Inc.Inventors: Glenn Fung, Marc Overhage, Jan DeHaan, Faisal Farooq, Balaji Krishnapuram, John D. Haley, Sebastian Philipp Brandt, Luigi Iannone, Nicholas Drummond, Ignazio Palmisano
-
Publication number: 20140149132Abstract: Managing clinical data documents may involve receiving hierarchically organized clinical document text of a plurality of different clinical documents comprised of text elements, text element qualifiers, and text element values. An analysis of the text elements, the text element qualifiers and the text element values of the received clinical documents may be performed. Clinical concepts in the received documents based on the analysis may be identified. An inventory of identified concepts may be generated. Clinical concepts may be combined to provide concept combinations, and a data structure model using the inventory and the concept combinations may be generated.Type: ApplicationFiled: November 22, 2013Publication date: May 29, 2014Inventors: Jan DeHaan, John D. Haley, Alan Rector, Sebastian Philipp Brandt, Samuel I. Brandt, Luigi Iannone, Nicholas Drummond
-
Patent number: 8575164Abstract: Methods and compositions for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound of Formula I, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by Formula I: wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein.Type: GrantFiled: February 25, 2008Date of Patent: November 5, 2013Assignee: OSI Pharmaceuticals, LLCInventors: Lee D. Arnold, Qun-Sheng Ji, Elizabeth Buck, John D. Haley, Mark J. Mulvihill
-
Patent number: 8388957Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided.Type: GrantFiled: November 11, 2011Date of Patent: March 5, 2013Assignee: OSI Pharmaceuticals, LLCInventor: John D. Haley
-
Patent number: 8383357Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors.Type: GrantFiled: April 13, 2007Date of Patent: February 26, 2013Assignee: OSI Pharmaceuticals, LLCInventors: John D. Haley, Stuart Thomson, Filippo Petti
-
Patent number: 8377636Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase.Type: GrantFiled: April 14, 2008Date of Patent: February 19, 2013Assignee: OSI Pharmaceuticals, LLCInventors: John D. Haley, Stuart Thompson
-
Publication number: 20120157480Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors.Type: ApplicationFiled: December 12, 2011Publication date: June 21, 2012Inventors: John D. Haley, Graeme Griffin, Lukas A. Amler, David A. Eberhard, Robert L. Yauch
-
Publication number: 20120122841Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Inventor: John D. Haley
-
Publication number: 20120101084Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, pErk, HER3 and pHER are also demonstrated to be effective biomarkers for predicting sensitivity of tumor cells to IGF-1R kinase inhibitors.Type: ApplicationFiled: October 27, 2011Publication date: April 26, 2012Inventors: John D. Haley, Elizabeth A. Buck
-
Patent number: 8093011Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by EGFR kinase inhibitors. Improved methods for treating cancer patients with EGFR kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to EGFR kinase inhibitors.Type: GrantFiled: March 16, 2006Date of Patent: January 10, 2012Inventors: John D. Haley, Graeme Griffin, Lukas A. Amler, David A. Eberhard, Robert L. Yauch
-
Patent number: 8062838Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-1R kinase inhibitors.Type: GrantFiled: September 19, 2006Date of Patent: November 22, 2011Assignee: OSI Pharmaceuticals, LLCInventor: John D. Haley
-
Patent number: 8048621Abstract: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an IGF-1R kinase inhibitor, comprising assessing whether the tumor cell has undergone an epithelial to mesenchymal transition (EMT), by determining the expression level of epithelial and/or mesenchymal biomarkers, wherein tumor cells that have undergone an EMT are substantially less sensitive to inhibition by IGF-1R kinase inhibitors. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methodology are also provided. Additionally, methods are provided for the identification of new biomarkers that are predictive of responsiveness of tumors to IGF-1R kinase inhibitors.Type: GrantFiled: September 29, 2008Date of Patent: November 1, 2011Assignee: OSI Pharmaceuticals, LLCInventors: John D. Haley, Elizabeth A. Buck
-
Patent number: 7951549Abstract: The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line H358, which are stimulated by receptor ligands to induce EMT, or which have been engineered to inducibly express a protein that stimulates EMT. The present invention also provides methods of identifying potential anti-cancer agents by using such tumor cell preparations to identify agents that inhibit EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells. Such agents should be particularly useful when used in conjunction with other anti-cancer drugs such as EGFR and IGF-1R kinase inhibitors, which appear to be less effective at inhibiting tumor cells that have undergone an EMT.Type: GrantFiled: March 6, 2009Date of Patent: May 31, 2011Assignee: OSI Pharmaceuticals, Inc.Inventors: John D. Haley, Stuart Thomson, Julie Kan, Salam A. Shaaban